HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Daratumumab, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for relapsed / refractory multiple myeloma and newly diagnose ...


Ibrutinib ( Imbruvica ) inhibits chronic lymphocytic leukemia ( CLL ) proliferation and effects prolonged remission without eradicating disease. Obinutuzumab ( Gazyvaro ) is an anti-CD20 monoclonal ...


Patients with relapsed or refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) or mantle cell lymphoma ( MCL ) have a poor prognosis and many do not have long-term disease control with salvage t ...


Polatuzumab vedotin ( Polivy ) combined with Rituximab ( MabThera ) has demonstrated activity and tolerability in a phase II trial of patients with relapsed / refractory ( R/R ) diffuse large B-cell l ...


Venetoclax ( Venclexta ) in newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a series of trials including two phase 3 trials, VIALE-A ( M15-656 ) an ...


Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy, according to a new study from researche ...


Current available therapies for patients with acute myeloid leukemia ( AML ) who are ineligible for intensive therapy yield limited responses with poor survival. Venetoclax ( Venclyxto ) is a sele ...


Central nervous system ( CNS ) relapse of mantle cell lymphoma ( MCL ) is a rare phenomenon for which a standard of care has not been identified. Responses to conventional treatment for CNS-MCL are ...


Based on in vitro studies, Polatuzumab vedotin + Obinutuzumab + Venetoclax ( Pola-G-Ven )may have significant anti-tumor activity in relapsed / refractory follicular lymphoma ( R/R FL ). Researchers ...


Immunochemotherapy is standard of care for patients with previously untreated advanced stage follicular lymphoma ( FL ). Four-year data from the phase III GALLIUM study have previously demonstrated ...


Selinexor ( Xpovio ) is an oral, selective inhibitor of XPO1-mediated nuclear export, leading to the reactivation of tumor suppressor proteins. In a phase 1b/2 study, the combination of once weekl ...


The treatment of relapsed or refractory diffuse large B-cell lymphoma ( R/R DLBCL ) remains challenging. Atezolizumab ( Tecentriq ) and Obinutuzumab ( Gazyvaro ) are monoclonal antibodies acting res ...


Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, has demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated relapsed / refractory mu ...


Outcomes are poor in triple-class exposed patients with relapsed and refractory multiple myeloma ( RRMM ) who progress on immunomodulatory agents ( IMiDs ), proteasome inhibitors ( PIs ), and CD38 ant ...


JNJ-68284528 ( JNJ-4528 ) is a chimeric antigen receptor T ( CAR-T ) cell therapy containing 2 B-cell maturation antigen ( BCMA)-targeting single-domain antibodies. Researchers have presented updat ...